BriaCell Therapeutics (BCTX) Competitors

Annovis Bio (NYSE:ANVS) and BriaCell Therapeutics (NASDAQ:BCTX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, community ranking, media sentiment and dividends.

Do institutionals and insiders hold more shares of ANVS or BCTX?

15.8% of Annovis Bio shares are owned by institutional investors. Comparatively, 15.4% of BriaCell Therapeutics shares are owned by institutional investors. 20.8% of Annovis Bio shares are owned by company insiders. Comparatively, 5.7% of BriaCell Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Does the MarketBeat Community favor ANVS or BCTX?

Annovis Bio received 19 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. Likewise, 91.43% of users gave Annovis Bio an outperform vote while only 86.67% of users gave BriaCell Therapeutics an outperform vote.

Company	Underperform	Outperform
Annovis Bio	Outperform Votes 32 91.43%	Underperform Votes 3 8.57%
BriaCell Therapeutics	Outperform Votes 13 86.67%	Underperform Votes 2 13.33%

Does the media favor ANVS or BCTX?

In the previous week, Annovis Bio had 12 more articles in the media than BriaCell Therapeutics. MarketBeat recorded 15 mentions for Annovis Bio and 3 mentions for BriaCell Therapeutics. Annovis Bio's average media sentiment score of 0.66 beat BriaCell Therapeutics' score of 0.30 indicating that Annovis Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Annovis Bio	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
BriaCell Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Which has more risk and volatility, ANVS or BCTX?

Annovis Bio has a beta of 1.62, suggesting that its share price is 62% more volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500.

Do analysts recommend ANVS or BCTX?

Annovis Bio currently has a consensus price target of $30.25, suggesting a potential upside of 978.43%. BriaCell Therapeutics has a consensus price target of $32.00, suggesting a potential upside of 816.91%. Given Annovis Bio's higher probable upside, analysts clearly believe Annovis Bio is more favorable than BriaCell Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Annovis Bio	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	3.00
BriaCell Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is ANVS or BCTX more profitable?

Company	Net Margins	Return on Equity	Return on Assets
Annovis Bio	N/A	N/A	-311.00%
BriaCell Therapeutics	N/A	N/A	-191.19%

Which has higher valuation and earnings, ANVS or BCTX?

Annovis Bio is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Annovis Bio	N/A	N/A	-$56.20M	-$2.16	-1.30
BriaCell Therapeutics	N/A	N/A	-$4.79M	-$5.03	-0.69

Summary

Annovis Bio beats BriaCell Therapeutics on 11 of the 14 factors compared between the two stocks.